JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (5): 1-5.doi: 10.6040/j.issn.1671-7554.0.2016.222

    Next Articles

A recombinant adenovirus fiber knob protein sensitizes ovarian cancer cells to cetuximab therapy

XIAO Junchao1, JIANG Wen2, NAN Hui3, WANG Peirong1   

  1. 1. Department of Pediatrics;
    2. Central Lab, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    3. Department of Pediatrics, Liaocheng Peoples Hospital, Liaocheng 252002, Shandong, China
  • Received:2016-03-04 Online:2016-05-16 Published:2016-05-16

PDF (PC)

406

Abstract: Objective To investigate whether Ad35K++ could enhance complement dependent cytotoxicity(CDC)triggered by cetuximab to ovarian cancer, and to explore the possible mechanisms. Methods The SK-OV-3 cells were incubated with Ad35K++, followed by cetuximab and normal human serum(NHS)treatment. CD46 expression of SK-OV-3 cells and apoptosis rate were measured with flow cytometry. The cell inhibition rate was detected with MTT array. The expression of Bcl-2 family and activation of caspase-3 were tested with Western blotting. Results CD46 level on the surface of SK-OV-3 cells was dramatically decreased after being incubated with Ad35K++. Ad35K++ sensitized SK-OV-3 cells to CDC triggered by cetuximab in vitro and enhanced complement mediated apoptosis. The expressions of Bax, cleaved-caspase 3, cleaved-PARP were upregulated and the expression of Bcl-2 was down-regulated. Conclusion Ad35K++ could enhance CDC triggered by cetuximab to ovarian cancer via the activation of mitochondria-mediated apoptotic pathway.

Key words: Ovarian cancer, CD46, Cetuximab, Ad35K++

CLC Number: 

  • R737.3
[1] Singh AP, Senapati S, Ponnusamy MP, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer[J]. Lancet Oncol, 2008, 9(11): 1076-1085.
[2] Lin KT, Yeh YM, Chuang CM, et al. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B[J]. Nat Commun, 2015, 6: 5917. doi: 10.1038/ ncomms6917.
[3] Seward SM, Winer I. Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma[J]. Cancer Metastasis Rev, 2015, 34(1): 5-10.
[4] Hsu YF, Ajona D, Corrales L, et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo[J]. Mol Cancer, 2010, 9: 139. doi: 10.1186/1476-4598-9-139.
[5] Wang H, Liu Y, Li ZY, et al. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy[J]. Blood, 2010, 115(3): 592-600.
[6] Luca T, Barresi V, Privitera G, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells[J]. Cell Prolif, 2014, 47(5): 435-447.
[7] Gomes SE, Simoes AE, Pereira DM, et al. miR-143 or miR-145 overexpression increases cetuximab mediated antibody-dependent cellular cytotoxicity in human colon cancer cells[J]. Oncotarget, 2016. doi: 10.18632/oncotarget.7010.[Epub ahead of print]
[8] Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer[J]. Cancer Res, 2015, 75(1): 22-30.
[9] Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer[J]. Immunol Res, 2014, 59(1-3): 203-210.
[10] Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer[J]. MAbs, 2014, 6(5): 1133-1144.
[11] Jackson SE, Chester JD. Personalised cancer medicine[J]. Int J Cancer, 2015, 137(2): 262-266.
[12] Mamidi S, Cinci M, Hasmann M, et al. Lipoplex mediated silencing of membrane regulators(CD46, CD55 and CD59)enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab[J]. Mol Oncol, 2013, 7(3): 580-594.
[13] Balakrishnan DD, Kumar SG. Higher Caspase-like activity in symptomatic isolates of Blastocystis spp[J]. Parasit Vectors, 2014, 7: 219. doi: 10.1186/1756-3305-7-219.
[14] Besbes S, Mirshahi M, Pocard M, et al. New dimension in therapeutic targeting of bcl-2 family proteins[J]. Oncotarget, 2015, 6(15): 12862-12871.
[1] LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 33-38.
[2] ZHAO Lu, JIAO Jun, ZHANG Teng, JIAO Xinlin, CUI Baoxia. Expression of LXRα in ovarian carcinoma and effects of T0901317 on SKOV3 cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 49-53.
[3] ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie. CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 24-29.
[4] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
[5] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[6] CHEN Jing, LI Chunyan, ZHAO Miaoqing, CUI Jingjing, ZHANG Na, FU Yibing. Expression of EZH2 protein and its role in ovarian epithelial tumor [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 65-70.
[7] QIU Huihui1， YE Liping1， WEN Youfeng2， LI Dan1， SONG Jia1. Effects of IL-6 on the expressions of bcl-2，cyclinD1 and VEGF in ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 17-21.
[8] LI Yan, WEI Wei, LV Shuqing, TIAN Yongjie. Effects of PARP-1 on angiogenesis of ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 97-101.
[9] ZHANG Miaoci, LI Ping, HA Minwin. Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 55-59.
[10] ZHANG Qing-lu, HOU Gui-hua, LIANG Ting, SONG Jing, ZHANG Chao. Effect and clinical significance of ISO-1 in the invasion
of ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 33-.
[11] QIAO Zhen1, LIU Pei-shu2, HAN Bing1, WANG Yu1. Smac mimic potentiates cisplatin-induced cell apoptosis of
ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(6): 61-.
[12] ZHANG Jing-jing1, WANG Zhe1, TIAN Yong-jie1, ZHANG Jie2. Effects of PJ34 on growth activity and cisplatin resistance of ovarian cancer C13* cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 46-50.
[13] ZHAO Shan,RONG Feng-nian,ZHOU Ting. Inhibitory effect of valproic acid on human ovarian cancer in nude mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 306-309.
[14] ZHANG Lan,LIU Pei-shu,WANG Xiu-ying,XIN Gang. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(12): 1276-1280.
[15] YI Cui-hua,HOU Ming,LI Li-zhen,ZHANG Xin,WEI Jun-min,LI Li,HAO Jing. Effects of RNAi on HER2/neu gene and proliferation of SKOV3 ovarian cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(10): 1048-1052.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd